BioCentury
ARTICLE | Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase I data

June 1, 2009 7:00 AM UTC

Data from 9 evaluable patients in a Phase I trial showed that OXi4503 produced a dose-dependent linear increase in peak plasma concentrations and AUC. Two multiple myeloma (MM) patients achieved stabl...